Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Feb;27(1):9-17.
doi: 10.1097/MOP.0000000000000179.

Advances in unrelated and alternative donor hematopoietic cell transplantation for nonmalignant disorders

Affiliations
Review

Advances in unrelated and alternative donor hematopoietic cell transplantation for nonmalignant disorders

Shalini Shenoy et al. Curr Opin Pediatr. 2015 Feb.

Abstract

Purpose of review: The role of hematopoietic cell transplantation in non-malignant disorders has increased exponentially with the recognition that multiple diseases can be controlled or cured if engrafted with donor-derived cells. This review provides an overview of advances made in alternative donor transplants for nonmalignant disorders.

Recent findings: Stem cell sources, novel transplant methods, and sophisticated supportive care have simultaneously made giant strides toward improving the safety and efficacy of hematopoietic cell transplantation. This has led to the utilization of marrow, cord, peripheral blood stem cell and haploidentical stem cell sources, and novel reduced toxicity or reduced intensity conditioning regimens to transplant non-malignant disorders such as immune dysfunctions, marrow failure syndromes, metabolic disorders and hemoglobinopathies. Transplant complications such as graft rejection, infections, and graft versus host disease are better combated in this modern era of medicine, achieving better survival with decreased late effects. These aspects of transplant for non-malignant disorders are discussed.

Summary: This review presents the progress made in the realm of hematopoietic cell transplantation for non-malignant disorders. It advocates the consideration of alternative donor transplants in the absence of human leukocyte antigen matched siblings when indicated by disease severity. The ultimate goal is to provide curative transplant options for more patients that can benefit from this intervention, prior to detrimental outcomes.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Pai S-Y, Logan B, Griffith LM, et al. Transplantation outcomes for severe combined immunodeficiency, 2000-2009. N Engl J Med. 2014;371:434–46. [Successful but low B cell engraftment.] - PMC - PubMed
    1. Boelens JJ, Aldenhoven M, Purtill D, et al. Outcomes of transplantation using various hematopoietic cell sources in children with Hurler syndrome after myeloablative conditioning. Blood. 2013;121:3981–7. [good outcomes but better with matched grafts; cord blood transplant outcomes were best.] - PMC - PubMed
    1. Myers KC, Davies S. Hematopoietic stem cell transplantation for bone marrow failure syndromes in children. Biol Blood Marrow Transplant. 2009;15(3):279–92. - PubMed
    1. King A, Shenoy S. Evidence-based focused review of the status of hematopoietic stem cell transplantation as treatment of sickle cell disease and thalassemia. Blood. 2014;123(20):3089–4. - PubMed
    1. EBMT WPIE: EBMT/ESID guideline for HCT for Primary Immunodeficiencies. http://www.ebmt.org/Contents/About-EBMT/Who-We-Are/ScientificCouncil/Doc....

Publication types

MeSH terms